勃起功能障碍

Lizza EF, Rosen RC. Definition and classification of erectile dysfunction: report of the nomenclature committee of the International Society of Impotence Research. Int J Impot Res. 1999 Jun;11(3):141-3.

• 摘要

Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018 May 7;200(3):633-41.

• 全文
• 摘要

Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012 Aug;87(8):766-78.

• 全文
• 摘要

Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997 Jun;49(6):822-30.

• 摘要

Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999 Dec;11(6):319-26.

• 摘要

1.  National Institutes of Health. Impotence: NIH consensus development panel on impotence. JAMA. 1993 Jul 7;270(1):83-90.

• 摘要

2.  Lizza EF, Rosen RC. Definition and classification of erectile dysfunction: report of the nomenclature committee of the International Society of Impotence Research. Int J Impot Res. 1999 Jun;11(3):141-3.

• 摘要

3.  Auld RB, Brock G. Sexuality and erectile dysfunction: results of a national survey. J Sex Reprod Med. 2002;2(2):50-4.

• 全文

4.  European Association of Urology. Guidelines on male sexual dysfunction. 2017 [internet publication].

• 全文

5.  Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res. 2000 Dec;12(6):305-11.

• 全文
• 摘要

6.  Moreira ED Jr, Lbo CF, Diament A, et al. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology. 2003 Feb;61(2):431-6.

• 摘要

7.  Schouten BW, Bosch JL, Bernsen RM, et al. Incidence rates of erectile dysfunction in the Dutch general population. Effects of definition, clinical relevance and duration of follow-up in the Krimpen Study. Int J Impot Res. 2005 Jan-Feb;17(1):58-62.

• 全文
• 摘要

8.  Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999 Feb 10;281(6):537-44.

• 全文
• 摘要

9.  Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994 Jan;151(1):54-61.

• 摘要

10.  Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000 Feb;163(2):460-3.

• 摘要

11.  Wessells H, Joyce GF, Wise M, et al. Erectile dysfunction. J Urol. 2007 May;177(5):1675-81.

• 摘要

12.  Saigal CS, Wessells H, Pace J, et al. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med. 2006 Jan 23;166(2):207-12.

• 全文
• 摘要

13.  Capogrosso P, Colicchia M, Ventimiglia E, et al. One patient out of four with newly diagnosed erectile dysfunction is a young man - worrisome picture from the everyday clinical practice. J Sex Med. 2013 Jul;10(7):1833-41.

• 摘要

14.  Goldstein I. Male sexual circuitry. Sci Am. 2000 Aug;283(2):70-5.

• 摘要

15.  Lue TF. Erectile dysfunction. N Engl J Med. 2000 Jun 15;342(24):1802-13.

• 摘要

16.  Romeo JH, Seftel AD, Madhun ZT, et al. Sexual function in men with diabetes type 2: association with glycemic control. J Urol. 2000 Mar;163(3):788-91.

• 摘要

17.  Lewis RW. Epidemiology of erectile dysfunction. Urol Clin North Am. 2001 May;28(2):209-16, vii.

• 摘要

18.  Maggi M, Buvat J, Corona G, et al. Hormonal causes of male sexual dysfunctions and their management (hyperprolactinemia, thyroid disorders, GH disorders, and DHEA). J Sex Med. 2013 Mar;10(3):661-77.

• 摘要

19.  Guay AT, Spark RF, Bansal S, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update. Endocr Pract. 2003 Jan-Feb;9(1):77-95.

• 摘要

20.  Morales A, Heaton JP. Hormonal erectile dysfunction. Evaluation and management. Urol Clin North Am. 2001 May;28(2):279-88.

• 摘要

21.  National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management. January 2014 [internet publication].

• 全文

22.  Andersson KE, Wagner G. Physiology of penile erections. Physiol Rev. 1995 Jan;75(1):191-236.

• 摘要

23.  Burnett AL. Nitric oxide in the penis: physiology and pathology. J Urol. 1997 Jan;157(1):320-4.

• 摘要

24.  Lincoln TM. Cyclic GMP and mechanisms of vasodilation. Pharmacol Ther. 1989;41(3):479-502.

• 摘要

25.  Saenz de Tejada I. Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res. 2000 Oct;12 Suppl 4:S34-8.

• 摘要

26.  Kwan M, Greenleaf WJ, Mann J, et al. The nature of androgen action on male sexuality: a combined laboratory/self-reported study on hypogonadal men. J Clin Endocrinol Metab. 1983 Sep;57(3):557-62.

• 摘要

27.  Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav. 1983 Feb;12(1):59-66.

• 摘要

28.  Giuliano F, Rampin OP, McKenna KE. Animal models used in the study of erectile dysfunction In: Carson CC, Kirby RS, Goldstein I, eds. Textbook of erectile dysfunction. Oxford: ISIS Medical Media; 1999:43-9.

29.  Rampin O, Giulaiano F. Brain control of penile erection. World J Urol. 2001 Feb;19(1):1-8.

• 摘要

30.  Reffelmann T, Kloner RA. Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag. 2006;2(4):447-55.

• 全文
• 摘要

31.  Burchardt M, Burchardt T, Baer L, et al. Hypertension is associated with severe erectile dysfunction. J Urol. 2000 Oct;164(4):1188-91.

• 摘要

32.  Maas R, Schwedhelm E, Albsmeier J, et al. The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med. 2002 Aug;7(3):213-25.

• 摘要

33.  Bacon CG, Hu FB, Giovannucci E, et al. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care. 2002 Aug;25(8):1458-63.

• 摘要

34.  Kim JH, Kim IK, Seo KK, et al. Involvement of superoxide radical in the impaired endothelium-dependent relaxation of cavernous smooth muscle in hypercholesterolemic rabbits. Urol Res. 1997;25(5):341-6.

• 摘要

35.  De Berardis G, Pellegrini F, Franciosi M, et al; Quality of Care and Outcomes in Type 2 Diabetes Study Group. Identifying patients with type 2 diabetes with a higher likelihood of erectile dysfunction: the role of the interaction between clinical and psychological factors. J Urol. 2003 Apr;169(4):1422-8.

• 摘要

36.  Stehouwer CD, Lamber J, Konker AJ, et al. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res. 1997 Apr;34(1):55-68.

• 摘要

37.  Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA. 2004 Jun 16;291(23):2847-50.

• 全文
• 摘要

38.  Feldman HA, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med. 2000 Apr;30(4):328-38.

• 摘要

39.  Burnett AL. Metabolic syndrome, endothelial dysfunction, and erectile dysfunction: association and management. Curr Urol Rep. 2005 Nov;6(6):470-5.

• 摘要

40.  Demir T, Demir O, Kefi A, et al. Prevalence of erectile dysfunction in patients with metabolic syndrome. Int J Urol. 2006 Apr;13(4):385-8.

• 摘要

41.  Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. 1982 Sep;128(3):492-7.

• 摘要

42.  Yeager ES, Van Heerden JA. Sexual dysfunction following proctocolectomy and abdominoperineal resection. Ann Surg. 1980 Feb;191(2):169-70.

• 全文
• 摘要

43.  Padma-Nathan H, McCullough A, Forest C. Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. Curr Urol Rep. 2004 Dec;5(6):467-71.

• 摘要

44.  Eardley I, Kirby R. Neurogenic impotence. In: Kirby RS, Carson CC, Webster GD, eds. Impotence: diagnosis and management of male erectile dysfunction. Oxford: Butterworth Heinemann; 1991:227.

45.  Wright JL, Nathens AB, Rivara FP, et al. Specific fracture configurations predict sexual and excretory dysfunction in men and women 1 year after pelvic fracture. J Urol. 2006 Oct;176(4 Pt 1):1540-5; discussion 1545.

• 摘要

46.  Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999 Feb;19(1):67-85.

• 摘要

47.  Ricchiuti VS, Haas CA, Seftel AD, et al. Pudendal nerve injury associated with avid bicycling. J Urol. 1999 Dec;162(6):2099-100.

• 摘要

48.  Egerdie RB, Auerbach S, Roehrborn CG, et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med. 2012 Jan;9(1):271-81.

• 摘要

49.  Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018 May 7;200(3):633-41.

• 全文
• 摘要

50.  Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012 Aug;87(8):766-78.

• 全文
• 摘要

51.  Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997 Jun;49(6):822-30.

• 摘要

52.  Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999 Dec;11(6):319-26.

• 摘要

53.  Moreland RB, Nehra A. Pathophysiology of Peyronie's disease. Int J Impot Res. 2002 Oct;14(5):406-10.

• 摘要

54.  Gholami SS, Gonzalez-Cadavid NF, Lin CS, et al. Peyronie's disease: a review. J Urol. 2003 Apr;169(4):1234-41.

• 摘要

55.  Lue TF, Giuliano F, Montorsi F, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2004 Jul;1(1):6-23.

• 摘要

56.  Spratt DI, Bigos ST, Beitins I, et al. Both hyper- and hypogonadotrophic hypogonadism occur transiently in acute illness: bio- and immunoactive gonadotropins. J Clin Endocrinol Metab. 1992 Dec;75(6):1562-70.

• 摘要

57.  Baskin HJ, Cobin RH, Duick DS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002 Nov-Dec;8(6):457-69.

• 摘要

58.  Montague DK, Jarow J, Broderick GA, et al. Premature ejaculation: guideline on the pharmacologic management of premature ejaculation. 2004 [internet publication].

• 全文

59.  Berger R, Billups K, Brock G, et al. Report of the American Foundation for Urologic Disease (AFUD) thought leader panel for evaluation and treatment of priapism. Int J Impot Res. 2001 Dec;13 Suppl 5:S39-43.

• 摘要

60.  Rosen RC, Cappelleri JC, Gendrano N. The international index of erectile function (IIEF): a state-of-the-science review. Int J Impot Res. 2002 Aug;14(4):226-44.

• 全文
• 摘要

61.  Cappelleri JC, Rosen RC, Smith MD, et al. Diagnostic evaluation of the erectile function domain of the international index of erectile function. Urology. 1999 Aug;54(2):346-51.

• 摘要

62.  European Association of Urology. Guidelines on male sexual dysfunction. 2018 [internet publication].

• 全文

63.  Shabsigh R, Duval S, Shah M, et al. Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: a meta-analysis of clinical trial data. Curr Med Res Opin. 2007 Oct;23(10):2453-60.

• 摘要

64.  Wing RR, Rosen RC, Fava JL, et al. Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med. 2010 Jan;7(1 Pt 1):156-65.

• 摘要

65.  Gupta BP, Murad MH, Clifton MM, et al. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2011 Nov 14;171(20):1797-803.

• 全文
• 摘要

66.  Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie's Disease: AUA Guideline. J Urol. 2015 Jun 9;194(3):745-53.

• 全文
• 摘要

67.  Salonia A, Adaikan G, Buvat J, et al. Sexual rehabilitation after treatment for prostate cancer-part 2: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2017 Mar;14(3):297-315.

• 全文
• 摘要

68.  Hatzimouratidis K, Salonia A, Adaikan G, et al. Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016 Mar 25;13(4):465-88.

• 摘要

69.  Nehra A. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. Mayo Clin Proc. 2009 Feb;84(2):139-48.

• 摘要

70.  Vardi M, Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002187.

• 全文
• 摘要

71.  Alhathal N, Elshal AM, Carrier S. Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review. Can Urol Assoc J. 2012 Aug;6(4):269-74.

• 全文
• 摘要

72.  Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998 May 14;338(20):1397-404.

• 摘要

73.  Hellstrom WJ, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl. 2002 Nov-Dec;23(6):763-71.

• 全文
• 摘要

74.  Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002 Oct;168(4 Pt 1):1332-6.

• 摘要

75.  Goldstein I, McCullough AR, Jones LA, et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med. 2012 Apr;9(4):1122-33.

• 摘要

76.  Azzouni F, Abu Samra K. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. J Sex Med. 2011 Oct;8(10):2894-903.

• 摘要

77.  Khera M, Goldstein I. Erectile dysfunction. BMJ Clin Evid. 2011 Jun 29;2011. pii: 1803.

• 全文
• 摘要

78.  National Institute for Health and Care Excellence. Erectile dysfunction: avanafil. August 2014 [internet publication].

• 全文

79.  Kim E, Seftel A, Goldfischer E, et al. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil. Curr Med Res Opin. 2014 Dec 2;31(2):379-89.

• 摘要

80.  Bella AJ, Deyoung LX, Al-Numi M, et al. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur Urol. 2007 Oct;52(4):990-1005.

• 摘要

81.  Hatzichristou D, Gambla M, Rubio-Aurioles E, et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med. 2008 Feb;25(2):138-46.

• 全文
• 摘要

82.  Rubio-Aurioles E, Kim ED, Rosen RC, et al. Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily. J Sex Med. 2009 May;6(5):1314-23.

• 摘要

83.  Washington SL 3rd, Shindel AW. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug Des Devel Ther. 2010 Sep 7;4:159-71.

• 摘要

84.  Rubio-Aurioles E, Porst H, Kim ED, et al. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med. 2012 May;9(5):1418-29.

• 摘要

85.  Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2006 Aug;50(2):351-9.

• 摘要

86.  Loeb S, Folkvaljon Y, Lambe M, et al. Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA. 2015 Jun 23-30;313(24):2449-55.

• 全文
• 摘要

87.  Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology. 2006 Aug;68(2):386-91.

• 摘要

88.  Babaei AR, Safarinejad MR, Kolahi AA, et al. Penile revascularization for erectile dysfunction: a systematic review and meta-analysis of effectiveness and complications. Urol J. 2009 Winter;6(1):1-7.

• 全文
• 摘要

89.  Melnik T, Soares BG, Nasselo AG. Psychosocial interventions for erectile dysfunction. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD004825.

• 全文
• 摘要

90.  Montorsi F, Adaikan G, Becher E, et al. Committee 26. Summary of the recommendations on sexual dysfunctions in men. In: Montorsi F, Basson R, Adaikan G, eds. Sexual medicine: sexual dysfunctions in men and women. Edition 2010. Paris: Editions 21; 2010:1265-82.

• 全文
• 摘要

91.  Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al; Medicated Urethral System for Erection (MUSE) Study Group. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med. 1997 Jan 2;336(1):1-7.

• 摘要

92.  Cookson MS, Nadig PW. Long-term results with vacuum constriction device. J Urol. 1993 Feb;149(2):290-4.

• 摘要

93.  Mulcahy JJ. Current approach to the treatment of penile implant infections. Ther Adv Urol. 2010 Apr;2(2):69-75.

• 全文
• 摘要

94.  Montorsi F, Brock G, Stolzenburg JU, et al. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT). Eur Urol. 2014 Mar;65(3):587-96.

• 摘要

95.  Philippou YA, Jung JH, Steggall MJ, et al. Penile rehabilitation for postprostatectomy erectile dysfunction. Cochrane Database Syst Rev. 2018 Oct 23;(10):CD012414.

• 全文
• 摘要

96.  Pisansky TM, Pugh SL, Greenberg RE, et al. Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial. JAMA. 2014 Apr 2;311(13):1300-7.

• 摘要

97.  King SH, Mayorov AV, Balse-Srinivasan P, et al. Melanocortin receptors, melanotropic peptides and penile erection. Curr Top Med Chem. 2007;7(11):1098-1106.

• 摘要

98.  Rosen RC, Diamond LE, Earle DC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to viagra. Int J Impot Res. 2004 Apr;16(2):135-42.

• 摘要

99.  Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008 Mar;179(3):1066-71.

• 摘要

100.  Yoshimura N, Kato R, Chancellor MB, et al. Gene therapy as future treatment of erectile dysfunction. Expert Opin Biol Ther. 2010 Sep;10(9):1305-14.

• 全文
• 摘要

101.  Cui X, Zhou J, Qin Z, et al. Acupuncture for erectile dysfunction: a systematic review. Biomed Res Int. 2016 Jan 17;2016:2171923.

• 全文
• 摘要

102.  Liaw RL, Srilatha B, Adaikan PG. Effects of hydrogen sulfide on erectile function and its possible mechanism(s) of action. J Sex Med. 2011 Jul;8(7):1853-64.

• 摘要

103.  Padma-Nathan H, Steers WD, Wicker PA. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo controlled study of 329 patients. Int J Clin Pract. 1998;52:375-379.

• 摘要

104.  Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res. 2001;13:192-199.

• 摘要

105.  McCullough AR, Barada JH, Fawzy A, et al. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology. 2002;60:28-36.

• 摘要

106.  Guay AT, Perez JB, Jacobson J, et al. Efficacy and safety of sildenafil for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl. 2001;22:793-797.

• 摘要

107.  Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol. 1996;155:802-815.

• 摘要

108.  Bennett AH, Carpenter AJ, Barada JH. An improved vasoactive drug combination for a pharmacological erection program. J Urol. 1991;146:1564-1565.

• 摘要

109.  Hatzichristou DG, Pescatori ES. Current treatments and emerging therapeutic approaches in male erectile dysfunction. BJU Int. 2001;88(suppl 3):11-17.

• 摘要

110.  Danesh-Meyer HV, Levin LA. Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association? Br J Ophthalmol. 2007 Nov;91(11):1551-5.

• 摘要

111.  Laties AM. Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. Drug Saf. 2009;32(1):1-18.

• 摘要

112.  Sadovsky R, Brock GB, Gutkin SW, et al. Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction. Int J Clin Pract. 2009 Aug;63(8):1214-30.

• 全文
• 摘要

113.  Begot I, Peixoto TC, Gonzaga LR, et al. A home-based walking program improves erectile dysfunction in men with an acute myocardial infarction. Am J Cardiol. 2015 Mar 1;115(5):571-5.

• 摘要